Literature DB >> 9634806

Removal of sialic acid from a glycoprotein in CHO cell culture supernatant by action of an extracellular CHO cell sialidase.

M J Gramer1, C F Goochee, V Y Chock, D T Brousseau, M B Sliwkowski.   

Abstract

We have directly tested the hypothesis that Chinese hamster ovary (CHO) cell-produced glycoproteins are subject to extracellular degradation by a sialidase endogenous to the CHO cell line. Factors important to understanding the potential for extracellular degradation are addressed including the glycoprotein specificity, subcellular source, mechanism of release, and stability of the sialidase activity. The extracellular CHO cell sialidase apparently originates from the cytosol of the cells, and is released to the cell culture supernatant as a result of damage to the cellular membrane. The extracellular sialidase is active toward a variety of CHO cell-produced glycoproteins, and can hydrolyze sialic acid from the recombinant glycoprotein gp120 in the culture supernatant. While measuring the actual degradation of a glycoprotein by extracellular CHO cell sialidase can be difficult, data presented here suggest that the level of degradation can be estimated indirectly by using a more convenient fluorescent substrate, 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid, to quantify sialidase activity. Degradation by sialidase is minimized through addition of the sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid to the culture supernatant. The results in this study suggest additional potential approaches for minimizing degradation by sialidase, including isolation of a sialidase-deficient CHO cell line.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9634806     DOI: 10.1038/nbt0795-692

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  14 in total

1.  Genetic engineering of α2,6-sialyltransferase in recombinant CHO cells and its effects on the sialylation of recombinant interferon-γ.

Authors:  L Monaco; A Marc; A Eon-Duval; G Acerbis; G Distefano; D Lamotte; J M Engasser; M Soria; N Jenkins
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells.

Authors:  François Lefloch; Bertrand Tessier; Sébastien Chenuet; Jean-Marc Guillaume; Pierre Cans; Jean-Louis Goergen; Annie Marc
Journal:  Cytotechnology       Date:  2006-12-29       Impact factor: 2.058

Review 3.  Detecting and minimizing glycosidase activities that can hydrolyze sugars from cell culture-produced glycoproteins.

Authors:  M J Gramer
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

4.  Degradative activities in a recombinant chinese hamster ovary cell culture.

Authors:  M S Lao; D Toth; G Danell; C Schalla
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

5.  Calnexin overexpression sensitizes recombinant CHO cells to apoptosis induced by sodium butyrate treatment.

Authors:  Chaya Mohan; Gyun Min Lee
Journal:  Cell Stress Chaperones       Date:  2008-07-29       Impact factor: 3.667

6.  Caspase activation, sialidase release and changes in sialylation pattern of recombinant human erythropoietin produced by CHO cells in batch and fed-batch cultures.

Authors:  Kok Hwee Chuan; Sing Fee Lim; Laurent Martin; Chee Yong Yun; Sophia O H Loh; Francoise Lasne; Zhiwei Song
Journal:  Cytotechnology       Date:  2006-09-20       Impact factor: 2.058

7.  Na-butyrate increases the production and alpha2,6-sialylation of recombinant interferon-gamma expressed by alpha2,6- sialyltransferase engineered CHO cells.

Authors:  D Lamotte; L Buckberry; L Monaco; M Soria; N Jenkins; J M Engasser; A Marc
Journal:  Cytotechnology       Date:  1999-01       Impact factor: 2.058

8.  Enhanced erythropoietin heterogeneity in a CHO culture is caused by proteolytic degradation and can be eliminated by a high glutamine level.

Authors:  M Yang; M Butler
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

9.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.

Authors:  Xiaotian Zhong; Jill F Wright
Journal:  Int J Cell Biol       Date:  2013-04-18

10.  Application of the Protein Maker as a platform purification system for therapeutic antibody research and development.

Authors:  Geneviève Hélie; Marie Parat; Frédéric Massé; Cory J Gerdts; Thomas P Loisel; Allan Matte
Journal:  Comput Struct Biotechnol J       Date:  2016-06-16       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.